You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 172 Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
172 Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy
Free

Authors

Citation

Mohamoud Y, Park Y, Tesfamichael D, et al
172 Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0172

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.